CNS
MCID: CNT035
MIFTS: 60

Central Nervous System Disease (CNS) malady

Categories: Neuronal diseases, Immune diseases

Aliases & Classifications for Central Nervous System Disease

Aliases & Descriptions for Central Nervous System Disease:

Name: Central Nervous System Disease 12 14
Central Nervous System Diseases 42
Cns Diseases 52
Cns Disorder 69
Cns 45

Classifications:



Summaries for Central Nervous System Disease

Disease Ontology : 12 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary : Central Nervous System Disease, also known as central nervous system diseases, is related to pediatric cns embryonal cell carcinoma and pediatric cns choriocarcinoma, and has symptoms including headache, hemiplegia and hyperexplexia. An important gene associated with Central Nervous System Disease is MOG (Myelin Oligodendrocyte Glycoprotein), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Neuroscience. The drugs Propofol and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 71 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...

Related Diseases for Central Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
id Related Disease Score Top Affiliating Genes
1 pediatric cns embryonal cell carcinoma 11.8
2 pediatric cns choriocarcinoma 11.7
3 arthrogryposis multiplex congenita cns calcification 11.7
4 ectodermal dysplasia intellectual disability cns malformation 11.7
5 macrocephaly, mental retardation, short stature, spastic paraplegia and cns malformations 11.7
6 melanocytic lesions of cns 11.7
7 retinopathy anemia cns anomalies 11.7
8 neuronitis 11.1
9 meningitis 11.1
10 nervous system disease 10.9
11 neuromyelitis optica 10.8
12 granulomatous amebic encephalitis 10.8
13 restless legs syndrome 10.8
14 intracranial abscess 10.8
15 meningoencephalitis 10.8
16 epidural abscess 10.8
17 amoebiasis due to free-living amoebae 10.7
18 alopecia-intellectual disability syndrome 10.5 MBP MOG PLP1
19 cervical adenoid basal carcinoma 10.5 IL1B MBP MOG
20 amyotrophic lateral sclerosis type 14 10.5 IFNG IL1B NOS2
21 charcot-marie-tooth disease 10.5 APP GFAP IL1B
22 status epilepticus 10.4 IFNG IL1B MBP MOG
23 lipomatosis, multiple symmetric 10.4 MAPT MBP MOG
24 ectodermal dysplasia bartalos type 10.4 IFNG IL1B NOS2
25 active cochlear meniere's disease 10.4 APP BDNF MBP
26 retinal artery occlusion 10.4 CCR1 IL1B NGF
27 neonatal jaundice 10.4 BDNF IFNG MBP MOG
28 niemann-pick disease 10.4 GFAP MBP MOG
29 persistent mullerian duct syndrome 10.4 MBP MOG PLP1
30 breast reconstruction 10.4 BDNF GFAP IL1B MBP
31 proximal symphalangism 10.4 CXCR3 IFNG MBP
32 pulmonary hemosiderosis 10.4 MBP MOG PLP1
33 articulation disorder 10.4 IFNG IL1B MBP MOG
34 complex regional pain syndrome 10.4 IFNG IL1B MBP MOG PLP1
35 balkan nephropathy 10.4 CXCR3 IFNG IL1B
36 leydig cell hypoplasia 10.4 GRM1 MBP NOS2
37 early yaws 10.4 APP IL1B MBP NGF
38 bone dysplasia azouz type 10.4 APP GFAP MAPT PLP1
39 benign eccrine breast spiradenoma 10.4 CXCR3 IFNG IL1B
40 parasitic protozoa infectious disease 10.4 CXCR3 IFNG IL1B
41 ichthyosis lamellar 2 10.4 APP GFAP MAPT MBP
42 allergic bronchopulmonary aspergillosis, familial 10.4 APP BACE1 CXCR3 MAPT
43 vaginal spindle cell epithelioma 10.4 APP IL1B MAPT
44 malignant renovascular hypertension 10.4 IFNG NGF
45 splenic marginal zone lymphoma 10.4 BDNF GFAP NOS2
46 urea cycle disorder 10.4 BDNF GFAP IL1B MBP NGF
47 ovarian mucinous adenocarcinoma 10.4 BACE1 BDNF GFAP IL1B NGF
48 keratomalacia 10.4 IFNG IL1B NOS2
49 personality disorder 10.4 BDNF GRM2 GRM5 MAPT
50 contagious pustular dermatitis 10.4 APP MAPT MBP

Graphical network of the top 20 diseases related to Central Nervous System Disease:



Diseases related to Central Nervous System Disease

Symptoms & Phenotypes for Central Nervous System Disease

UMLS symptoms related to Central Nervous System Disease:


headache, hemiplegia, hyperexplexia

MGI Mouse Phenotypes related to Central Nervous System Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 APP BACE1 BDNF GFAP GRM1 GRM2
2 homeostasis/metabolism MP:0005376 10.41 IFNG IL1B MAPT MBP NGF NOS2
3 cellular MP:0005384 10.4 GRM1 GRM2 IFNG MAPT MBP MOG
4 growth/size/body region MP:0005378 10.39 APP BACE1 BDNF GFAP GRM1 GRM5
5 mortality/aging MP:0010768 10.28 APP BACE1 BDNF CCR1 CXCR3 GFAP
6 cardiovascular system MP:0005385 10.24 CCR1 CXCR3 GFAP HRH3 IFNG IL1B
7 immune system MP:0005387 10.23 APP CCR1 CXCR3 GFAP HRH3 IFNG
8 hematopoietic system MP:0005397 10.19 APP CCR1 CXCR3 IFNG IL1B MAPT
9 nervous system MP:0003631 10.19 NOS2 PLP1 PROM1 APP BACE1 BDNF
10 integument MP:0010771 10.13 MAPT NGF NOS2 APP BACE1 BDNF
11 muscle MP:0005369 10.07 GRM1 IFNG MAPT MOG NGF NOS2
12 neoplasm MP:0002006 9.87 IL1B MAPT NOS2 PROM1 CXCR3 GRM1
13 no phenotypic analysis MP:0003012 9.7 APP BACE1 BDNF IFNG MAPT NGF
14 normal MP:0002873 9.65 APP BACE1 BDNF CXCR3 GFAP IFNG
15 vision/eye MP:0005391 9.36 GFAP GRM1 IFNG MAPT MBP MOG

Drugs & Therapeutics for Central Nervous System Disease

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1116)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
2
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206
3
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
4
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
5
Lacosamide Approved Phase 4,Phase 3,Phase 2 860352-01-8, 175481-36-4 219078
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
7
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
8
Baclofen Approved Phase 4,Phase 2 1134-47-0 2284
9
Ketorolac Approved Phase 4,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
10
Metoclopramide Approved, Investigational Phase 4,Phase 3,Phase 2 364-62-5 4168
11
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
12
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
13
Morphine Approved, Investigational Phase 4 57-27-2 5288826
14
Ziconotide Approved Phase 4 107452-89-1 447451
15
Milnacipran Approved Phase 4 92623-85-3 65833
16
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
17
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651 908828, 9651
18
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
19
Rasagiline Approved Phase 4,Phase 2,Phase 3 136236-51-6 3052776
20
Acetylcholine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-84-3 187
21
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1 137-58-6 3676
22
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
23
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
24
Memantine Approved, Investigational Phase 4,Phase 3,Phase 1 19982-08-2 4054
25
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
26
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
27
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
28
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
29
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 4342-03-4 5351166
30
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85622-93-1 5394
31
Zonisamide Approved, Investigational Phase 4,Phase 3 68291-97-4 5734
32
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 298-46-4 2554
33
Oxcarbazepine Approved Phase 4,Phase 3,Phase 1 28721-07-5 34312
34 Piracetam Approved Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
35
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
36
Coal tar Approved Phase 4,Phase 2,Phase 1 8007-45-2
37
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
38
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
39
Fluconazole Approved Phase 4,Phase 3,Phase 1 86386-73-4 3365
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
41
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22204-53-1 1302 156391
42
Sumatriptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 103628-46-2 5358
43
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
44
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
45
Prochlorperazine Approved, Vet_approved Phase 4,Phase 1,Phase 2 1984-02-6, 58-38-8 4917
46
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
48
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
49
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1 79617-96-2 68617
50
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4
2 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
3 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
4 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4
5 Cognitive and Behavioral Effects of Lacosamide Unknown status NCT01175954 Phase 4
6 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4
7 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
8 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
9 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
10 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
11 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4
12 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
13 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4
14 A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine Unknown status NCT01267864 Phase 4
15 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
16 A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function Unknown status NCT01712477 Phase 4
17 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4
18 Growth Hormone and Brain Functioning After Traumatic Brain Injury Unknown status NCT01699308 Phase 4
19 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4
20 Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy Unknown status NCT01992562 Phase 4
21 Occipital Transcutaneous Stimulation in Chronic Migraine Unknown status NCT02307071 Phase 4
22 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4
23 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4
24 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
25 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4
26 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
27 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
28 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Unknown status NCT01386255 Phase 4
29 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4
30 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4
31 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
32 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4
33 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4
34 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
35 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4
36 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
37 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
38 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4
39 Dexmedetomidine in Patients After Intracranial Surgery Completed NCT01445639 Phase 4
40 Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China Completed NCT01340950 Phase 4
41 Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study Completed NCT01348282 Phase 4
42 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease Completed NCT01662414 Phase 4
43 Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment Completed NCT02506686 Phase 4
44 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4
45 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4
46 A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) Completed NCT01278173 Phase 4
47 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4
48 Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage Completed NCT00119080 Phase 4
49 Dexmedetomidine Verses Propofol for Paediatric MRI Brain Completed NCT02776189 Phase 4
50 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Genetic Tests for Central Nervous System Disease

Anatomical Context for Central Nervous System Disease

MalaCards organs/tissues related to Central Nervous System Disease:

39
Brain, Spinal Cord, T Cells, Testes, Myeloid, Liver, Pituitary

Publications for Central Nervous System Disease

Articles related to Central Nervous System Disease:

(show top 50) (show all 297)
id Title Authors Year
1
Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. ( 28075486 )
2017
2
AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-Th17 Axis. ( 27354217 )
2016
3
Central nervous system disease and genital disease in harbor porpoises (Phocoena phocoena) are associated with different herpesviruses. ( 26861818 )
2016
4
Delivery of an adeno-associated virus vector into CSF attenuates central nervous system disease in mucopolysaccharidosis type II mice. ( 27510804 )
2016
5
Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. ( 26831951 )
2016
6
Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease - Six States, 2013-2015. ( 27608169 )
2016
7
Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe'sA disease). ( 27638585 )
2016
8
Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. ( 26997880 )
2016
9
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability. ( 27133811 )
2016
10
Clinical and Laboratory Findings That Differentiate Herpes Simplex Virus Central Nervous System Disease from Enteroviral Meningitis. ( 27563314 )
2016
11
Central nervous system disease in childhood acute lymphoblastic leukaemia- a review. ( 26990196 )
2016
12
Glial biomarkers in human central nervous system disease. ( 27228454 )
2016
13
Hodgkin Lymphoma With Central Nervous System Disease at Primary Presentation. ( 26814676 )
2016
14
Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. ( 25677878 )
2015
15
Macaque species susceptibility to simian immunodeficiency virus: increased incidence of SIV central nervous system disease in pigtailed macaques versus rhesus macaques. ( 25672885 )
2015
16
Intranasal delivery of stem cells as therapy for central nervous system disease. ( 25645932 )
2015
17
Targeted Temperature Management in Pediatric Central Nervous System Disease. ( 26042193 )
2015
18
Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. ( 25641427 )
2015
19
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. ( 25474439 )
2015
20
Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease. ( 26793168 )
2015
21
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? ( 26314739 )
2015
22
Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report. ( 26390826 )
2015
23
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. ( 26447927 )
2015
24
Current developments in understanding of West Nile virus central nervous system disease. ( 24722324 )
2014
25
Coxsackievirus-induced acute neonatal central nervous system disease model. ( 24696707 )
2014
26
Neonatal Herpes Simplex Virus Type-1 Central Nervous System Disease with Acute Retinal Necrosis. ( 24378951 )
2014
27
ELR(+) chemokine signaling in host defense and disease in a viral model of central nervous system disease. ( 24987333 )
2014
28
RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. ( 25258010 )
2014
29
Distinct systemic and central nervous system disease patterns in enterovirus and parechovirus infected children. ( 24662038 )
2014
30
A coumarin-based fluorescent probe as a central nervous system disease biomarker. ( 25390405 )
2014
31
RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease. ( 24043899 )
2013
32
The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease. ( 23889991 )
2013
33
Detection and characterization of a divergent avian reovirus strain from a broiler chicken with central nervous system disease. ( 23771766 )
2013
34
HIV-Associated Central Nervous System Disease in Patients Admitted at the Douala General Hospital between 2004 and 2009: A Retrospective Study. ( 23533732 )
2013
35
Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. ( 24124621 )
2013
36
Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. ( 23692640 )
2013
37
Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. ( 21692072 )
2012
38
Liposomal cytarabine in central nervous system disease of haematological malignancies: more effective but more toxic? ( 22484630 )
2012
39
Post-transplant lymphoproliferative disorder: the significance of central nervous system disease. ( 22717024 )
2012
40
Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. ( 22680628 )
2012
41
Magnetic resonance spectroscopy--a non-invasive method in evaluating focal and diffuse central nervous system disease. ( 23346244 )
2012
42
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. ( 22675662 )
2012
43
Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. ( 21387369 )
2011
44
Adenoviral infection presenting as an isolated central nervous system disease without detectable viremia in two children after stem cell transplantation. ( 21490187 )
2011
45
A plasma microRNA signature of acute lentiviral infection: biomarkers of central nervous system disease. ( 21857495 )
2011
46
Epilepsy and other central nervous system diseases in atypical autism: a case control study. ( 21207076 )
2011
47
Impact of induced pluripotent stem cells on the study of central nervous system disease. ( 21277194 )
2011
48
Methamphetamine and lentivirus interactions: reciprocal enhancement of central nervous system disease. ( 20608774 )
2010
49
High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases. ( 19969379 )
2010
50
The open issue of central nervous system disease in pediatric acute myeloid leukemia. ( 20658608 )
2010

Variations for Central Nervous System Disease

Expression for Central Nervous System Disease

Search GEO for disease gene expression data for Central Nervous System Disease.

Pathways for Central Nervous System Disease

Pathways related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 11.95 BDNF IL1B NGF PLP1
2 11.79 APP BACE1 GFAP GRM1 GRM2 GRM5
3 11.73 IFNG IL1B NOS2
4 11.67 IFNG IL1B NOS2
5
Show member pathways
11.65 APP BDNF NGF
6 11.62 CXCR3 IFNG IL1B
7
Show member pathways
11.52 APP BDNF NGF
8 11.51 BDNF GFAP IFNG IL1B MBP NOS2
9
Show member pathways
11.47 IFNG IL1B NOS2
10 11.46 BDNF GFAP MOG NGF PROM1
11 11.42 APP BACE1 GRM5
12 11.37 APP BACE1 MAPT
13 11.26 IFNG IL1B NOS2
14 11.2 APP BACE1 MAPT
15 11.07 IFNG IL1B NOS2
16 10.71 BDNF GRM1
17 10.64 GRM1 GRM2 GRM5
18 10.41 MBP PLP1

GO Terms for Central Nervous System Disease

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 APP BACE1 CCR1 CXCR3 GRM1 GRM2
2 axon GO:0030424 9.62 APP BACE1 GRM2 MAPT
3 presynaptic membrane GO:0042734 9.43 GRM1 GRM2 GRM5
4 neuron projection GO:0043005 9.35 APP GRM1 GRM2 GRM5 IFNG
5 integral component of plasma membrane GO:0005887 9.28 APP BACE1 CCR1 CXCR3 GRM1 GRM2

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.83 APP IFNG IL1B NGF PLP1
2 negative regulation of gene expression GO:0010629 9.76 CCR1 IFNG MAPT NOS2
3 locomotory behavior GO:0007626 9.73 APP GRM1 GRM5
4 regulation of insulin secretion GO:0050796 9.71 IFNG IL1B NOS2
5 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 IFNG IL1B
6 positive regulation of chemokine biosynthetic process GO:0045080 9.55 IFNG IL1B
7 chemical synaptic transmission GO:0007268 9.55 GRM1 GRM2 GRM5 MBP PLP1
8 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.52 IFNG IL1B
9 amyloid fibril formation GO:1990000 9.51 APP MAPT
10 regulation of defense response to virus by host GO:0050691 9.49 IFNG IL1B
11 axon ensheathment GO:0008366 9.48 MBP PLP1
12 regulation of synaptic transmission, glutamatergic GO:0051966 9.43 GRM1 GRM2 GRM5
13 positive regulation of killing of cells of other organism GO:0051712 9.4 IFNG NOS2
14 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 9.37 GRM1 GRM5
15 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG IL1B
16 G-protein coupled glutamate receptor signaling pathway GO:0007216 9.13 GRM1 GRM2 GRM5
17 adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway GO:0007196 8.8 GRM1 GRM2 GRM5

Molecular functions related to Central Nervous System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.8 CCR1 CXCR3 GRM1 GRM2 GRM5 HRH3
2 signal transducer activity GO:0004871 9.55 CCR1 CXCR3 GRM1 GRM2 HRH3
3 structural constituent of myelin sheath GO:0019911 9.26 MBP PLP1
4 neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration GO:0099583 8.96 GRM1 GRM5
5 glutamate receptor activity GO:0008066 8.8 GRM1 GRM2 GRM5

Sources for Central Nervous System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....